
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech is expected to see continued revenue growth and a reduction in net losses, driven by strong demand for its surgical soft tissue repair products, as well as potential future launches of new products or services. The company's cash and debt positions are relatively stable, providing sufficient capital for near-term operations. However, there are risks to achieving the 12-month price target, including potential obstacles to revenue growth and potential dilution risk. Overall, analysts recommend a Buy rating for the stock with a 12-month price target of $36 per share.
Bears say
Sanara MedTech is expected to see topline growth in the range of 13-17% in 2026, driven by the recent Vizient contract and the expected launch of OsStic bioadhesive. Despite the company's positive progress in securing contracts and expanding its product portfolio, its heavy reliance on new product launches for future growth and high levels of debt could pose risks to its financial stability. Additionally, negative market sentiment towards the overall medical technology industry could further impact the company's stock performance.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares